TITLE,SUMMARY,DATE
Sanofi: New Data From Phase 3 CADENZA Study On Sutimlimab,"June 11 (Reuters) - Sanofi SA <SASY.PA>::NEW PIVOTAL DATA AT EHA 2021 REINFORCES SUTIMLIMAB AS A FIRST-IN-CLASS INVESTIGATIONAL C1S INHIBITOR WITH THE POTENTIAL TO BE THE FIRST APPROVED TREATMENT FOR HEMOLYSIS IN PEOPLE WITH CAD, A SERIOUS AND CHRONIC AUTOIMMUNE HEMOLYTIC ANEMIA.PHASE 3 DATA FROM CADENZA STUDY MET PRIMARY COMPOSITE ENDPOINT WITH STATISTICAL SIGNIFICANCE; SECONDARY ENDPOINT DATA WERE CLINICALLY MEANINGFUL.FINDINGS PROVIDE FURTHER EVIDENCE THAT SUTIMLIMAB RESULTS IN RAPID INHIBITION OF C1-ACTIVATED HEMOLYSIS WITHIN ONE WEEK OF TREATMENT AND HAD A SUSTAINED TREATMENT EFFECT THROUGHOUT THE STUDY.",a day ago
"Sanofi, Capgemini, Generali And Orange Create Future4care To Develop E-Health Solutions","June 10 (Reuters) - SANOFI <SASY.PA>, CAPGEMINI <CAPP.PA>, GENERALI <GASI.MI> AND ORANGE <ORAN.PA>::SANOFI <<<SASY.PA>>>, CAPGEMINI <<<CAPP.PA>>>, GENERALI <<<GASI.MI>>> AND ORANGE <<<ORAN.PA>>> ANNOUNCE THE CREATION OF FUTURE4CARE.FUTURE4CARE IS A EUROPEAN STARTUP ACCELERATOR THAT AIMS AT THE RAPID DEVELOPMENT OF E-HEALTH SOLUTIONS.FUTURE4CARE ALSO AIMS AT THE CREATION OF AN INSTITUTE OFFERING CONTENT RELATED TO DIGITAL HEALTH.STARTUPS AND FUTURE4CARE PARTNERS WILL HAVE ACCESS TO A 6,000 M2 SPACE IN PARIS WHICH WILL OPEN IN DECEMBER 2021.SEPTEMBER 2021: LAUNCH OF THE FIRST CALL FOR PROPOSALS FOR STARTUPS.NOVEMBER 2021: ONBOARDING OF STARTUPS AND LAUNCH OF THE SERVICE OFFER IN ITS 100% DIGITAL VERSION. (Gdansk Newsroom). ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;)).",3 days ago
Healthcare group Sanofi partners with academic groups to study amcenestrant for breast cancer treatment,"June 4 (Reuters) - Sanofi SA <SASY.PA>::Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical research.Collaborating on the Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s investigational amcenestrant in estrogen receptor-positive (ER+) patients who prematurely discontinue standard therapy and have high risk of disease recurrence.Parties to finalize full terms of this cooperative effort.",9 days ago
Sanofi And Merck's Six-In-One Pediatric Combination Vaccine Available In U.S.,June 1 (Reuters) - SANOFI SA <SASY.PA>::SANOFI AND MERCK'S FIRST AND ONLY SIX-IN-ONE PEDIATRIC COMBINATION VACCINE NOW AVAILABLE IN UNITED STATES.,12 days ago
Sanofi Halts Venglustat Clinical Program In ADKPD,June 1 (Reuters) - Sanofi SA <SASY.PA>::REG-SANOFI PROVIDES UPDATE ON VENGLUSTAT CLINICAL PROGRAM.PIVOTAL PHASE 2/3 STUDY OF VENGLUSTAT IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) DID NOT MEET FUTILITY CRITERIA.COMPANY HAS HALTED CLINICAL PROGRAM IN ADPKD.SAFETY PROFILE OF VENGLUSTAT REMAINS CONSISTENT WITH PREVIOUSLY REPORTED RESULTS WITH MORE THAN 500 PATIENTS TREATED TO DATE OVER A PERIOD OF UP TO FOUR YEARS ACROSS ALL CLINICAL PROGRAMS.,12 days ago
"Sanofi, GSK Start Global Phase 3 Clinical Efficacy Study Of COVID-19 Vaccine Candidate","May 27 (Reuters) - Sanofi SA <SASY.PA>::SANOFI AND GSK INITIATE GLOBAL PHASE 3 CLINICAL EFFICACY STUDY OF COVID-19 VACCINE CANDIDATE.TWO-STAGE DESIGN WILL EVALUATE VACCINE FORMULATIONS TARGETING ORIGINAL D.614 VIRUS AS WELL AS B.1.351 VARIANT, IN DIVERSE GEOGRAPHIES WITH MULTIPLE CIRCULATING VARIANTS.A BOOSTER STUDY PROGRAM WILL BEGIN IN COMING WEEKS TO COMPLEMENT PHASE 3 TRIAL.PENDING POSITIVE PHASE 3 OUTCOMES AND REGULATORY REVIEWS, VACCINE COULD BE APPROVED IN Q4 2021.PRIMARY ENDPOINT OF STUDY IS PREVENTION OF SYMPTOMATIC COVID-19 IN SARS-COV-2 NAÏVE ADULTS.SECONDARY ENDPOINTS BEING PREVENTION OF SEVERE COVID-19 DISEASE AND PREVENTION OF ASYMPTOMATIC INFECTION.",17 days ago
TrialSpark Announces Collaboration With Sanofi,May 26 (Reuters) - TrialSpark::TRIALSPARK AND SANOFI ANNOUNCE COLLABORATION TO ACCELERATE COPD CLINICAL DEVELOPMENT.,18 days ago
Sanofi: Libtayo (Cemiplimab) Receives Positive CHMP Opinion For Treatment In Europe Of Two Advanced Cancers,May 24 (Reuters) - SANOFI SA <SASY.PA>::LIBTAYO (CEMIPLIMAB) RECEIVES POSITIVE CHMP OPINION FOR TREATMENT IN EUROPE OF TWO ADVANCED CANCERS.LIBTAYO RECOMMENDED FOR APPROVAL IN THE FIRST-LINE TREATMENT OF CERTAIN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE ≥50% PD-L1 EXPRESSION.CHMP HAS NOW ISSUED THREE POSITIVE OPINIONS FOR LIBTAYO IN ADVANCED CANCERS.LIBTAYO ALSO RECOMMENDED FOR APPROVAL IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO A HEDGEHOG PATHWAY INHIBITOR.,20 days ago
Libtayo (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers,May 24 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON- EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINIONS FOR LIBTAYO (CEMIPLIMAB) AS MONOTHERAPY IN 2 ADVANCED CANCERS.CHMP HAS NOW ISSUED THREE POSITIVE OPINIONS FOR LIBTAYO IN ADVANCED CANCERS.REGENERON-LIBTAYO APPROVAL RECOMMENDED IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO'VE PROGRESSED OR ARE INTOLERANT TO HEDGEHOGPATHWAY INHIBITOR.,20 days ago
Sanofi Says Amcenestrant In Combination With Palbociclib Showed Encouraging Antitumor Activity,"May 20 (Reuters) - SANOFI SA <SASY.PA>::ANNOUNCED ON WEDNESDAY AMCENESTRANT IN COMBINATION WITH PALBOCICLIB SHOWED ENCOURAGING ANTITUMOR ACTIVITY .IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE(ER+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC BREAST CANCER (MBC).AMCENESTRANT ACHIEVED OBJECTIVE RESPONSE RATE OF 34% AND CLINICAL BENEFIT RATE OF 74% IN PHASE 1 STUDY (AMEERA-1) IN COMBINATION WITH PALBOCICLIB.OVERALL SAFETY PROFILE OF AMCENESTRANT WITH PALBOCICLIB IS CONSISTENT WITH WHAT WAS OBSERVED IN MONOTHERAPY, WITHOUT SIGNS OF SIGNIFICANT CARDIAC OR OCULAR SIDE EFFECTS .PHASE 3 COMBINATION STUDY (AMEERA-5) OF AMCENESTRANT WITH PALBOCICLIB IN THE FIRST-LINE SETTING WAS INITIATED IN OCTOBER 2020 AND IS SUCCESSFULLY RECRUITING PATIENTS.PIVOTAL STUDY (AMEERA-3) OF AMCENESTRANT VERSUS PHYSICIAN’S CHOICE IN LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER IS FULLY RECRUITED; READOUT EXPECTED IN H2 2021.",24 days ago
ADA didn't require Sanofi to allow sales reps' 'job sharing',A U.S. appeals court on Tuesday ruled that Sanofi-Aventis U.S. LLC was not required to allow a pharmaceutical sales representative with an autoimmune disease to share her job duties with a coworker in order to accommodate her disability.,4 days ago
"Sanofi, GSK kick off Phase III trial for COVID-19 shot",France's Sanofi and Britain's GlaxoSmithKline launched a late-stage human trial for a recombinant COVID-19 vaccine candidate on Thursday which they hope to get approved by the end of 2021.,17 days ago
EU expects to get more than a billion COVID-19 shots by September,"The European Union expects to have received more than a billion doses of COVID-19 vaccines by the end of September from four drugmakers, according to a document presented to EU leaders on Tuesday.",18 days ago
"Mexico to begin phase three trials of Sanofi, Walvax COVID-19 vaccines",Mexico Foreign Minister Marcel Ebrard said on Monday the country will soon begin phase three trials for COVID-19 vaccines by France's Sanofi and China's Walvax.,19 days ago
Sanofi-GSK report positive interim results for their COVID-19 shot,"An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday.",a month ago
Sanofi/GSK report positive interim results for their COVID-19 shot,"An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday.",a month ago
BRIEF-Sanofi Exec Roman Chicz Says Expect To Start Global Late-Stage Study Of Covid-19 Vaccine In Q2 File Regulatory Submissions In H2 2021- World Vaccine Congress 2021,* EXEC ROMAN CHICZ SAYS EXPECT TO START GLOBAL LATE-STAGE STUDY OF COVID-19 VACCINE IN Q2; FILE REGULATORY SUBMISSIONS IN H2 2021- WORLD VACCINE CONGRESS 2021,a month ago
Drug giants offer pandemic recovery sleeper trade,"Pharmaceutical stock market stragglers could be in store for a post-pandemic booster shot. Shares of companies like GlaxoSmithKline, Novartis and Sanofi struggled during lockdown as routine procedures and treatments were postponed. But a reopening economy should restore...",a month ago
Eczema treatment and vaccines lift Sanofi first quarter results,Sanofi confirmed its 2021 targets after it posted stronger-than-expected first quarter results as sales of its star eczema treatment as well as flu and polio vaccines helped offset a dip in cough and cold treatments dented by lockdowns.,2 months ago
Dupixent and vaccines lift Sanofi first-quarter results,"Sanofi confirmed its 2021 targets on Wednesday after it posted stronger-than-expected results in the first quarter, helped by sales of its star eczema treatment Dupixent and vaccines.",2 months ago
France's Sanofi to help Moderna manufacture COVID-19 shots,"Sanofi will fill and pack millions of Moderna COVID-19 vaccines from September in an effort to help meet the demand for the U.S. drugmaker's shots, the French company said on Monday.",2 months ago
"UPDATE 2-C4X Discovery signs $500 mln Sanofi licensing deal, shares jump",Drug developer C4X Discovery said on Monday it had signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi to develop an oral therapy to treat inflammatory diseases.,2 months ago
C4X Discovery signs licensing deal with Sanofi worth up to $492 mln,Drug developer C4X Discovery said on Monday it has signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi to develop an oral therapy for treatment of inflammatory diseases.,3 months ago
Sanofi to invest 400 million euros in new vaccine production site in Singapore,French drugmaker Sanofi said on Monday it would invest 400 million euros ($475.40 million) over five years in a new vaccine production site in Singapore.,3 months ago
"Sanofi to build $925-million Toronto flu vaccine facility, creating 1,200 jobs","Sanofi will build a $925 million flu vaccine manufacturing facility in Toronto, creating 1,225 jobs and boosting Canada's access to vaccines in the event of a flu pandemic, the Canadian government said on Wednesday.",3 months ago
"Sanofi, Translate Bio launch human trial of mRNA COVID-19 vaccine","Sanofi and Translate Bio said on Friday they had started a human trial of their mRNA COVID-19 vaccine candidate, the French drugmaker's second vaccine project, which follows a protein-based shot hit by a delay last year.",4 months ago
GSK and Sanofi start with new COVID-19 vaccine study after setback,"GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot's launch.",4 months ago
France's Sanofi to help Johnson & Johnson manufacture COVID-19 vaccine,"French healthcare company Sanofi will provide COVID-19 vaccine manufacturing support to U.S. peer Johnson & Johnson, Sanofi said on Monday.",4 months ago
"GSK, Sanofi begin new COVID-19 vaccine trial of protein-based vaccine",Britain's GlaxoSmithKline and France's Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate and aim to reach the final testing stage in the second quarter.,4 months ago
"BRIEF-Sanofi, GSK Start New Phase 2 Study Of Adjuvanted Recombinant Protein-Based COVID-19 Vaccine Candidate",* GLAXOSMITHKLINE PLC - SANOFI AND GSK INITIATE NEW PHASE 2 STUDY,4 months ago
